Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

NCT07035561 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hypersenstivity Pneumonitis
ILD

Interventions

DRUG: Rituximab (Mabthera)

Sponsor

Shereen Medhat Mohammed Elsayed Nassar